The rise of innovative clinical trial designs: what's in it for amyotrophic lateral sclerosis?
Amyotroph Lateral Scler Frontotemporal Degener
.
2020 Feb;21(1-2):3-4.
doi: 10.1080/21678421.2019.1681455.
Epub 2019 Oct 29.
Authors
Ruben P A van Eijk
1
2
,
Angela Genge
3
Affiliations
1
Department of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands.
2
Biostatistics & Research Support, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
3
Department of Neurology, Clinical Research Unit, Montreal Neurological Institute, McGill University, Montreal, Canada.
PMID:
31661983
DOI:
10.1080/21678421.2019.1681455
No abstract available
Publication types
Editorial
Comment
MeSH terms
Amyotrophic Lateral Sclerosis*
Creatine
Humans
Tamoxifen
Substances
Tamoxifen
Creatine